Your browser doesn't support javascript.
loading
Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
Zurawski, Gerard; Shen, Xiaoying; Zurawski, Sandra; Tomaras, Georgia D; Montefiori, David C; Roederer, Mario; Ferrari, Guido; Lacabaratz, Christine; Klucar, Peter; Wang, Zhiqing; Foulds, Kathryn E; Kao, Shing-Fen; Yu, Xuesong; Sato, Alicia; Yates, Nicole L; LaBranche, Celia; Stanfield-Oakley, Sherry; Kibler, Karen; Jacobs, Bertram; Salazar, Andres; Self, Steve; Fulp, William; Gottardo, Raphael; Galmin, Lindsey; Weiss, Deborah; Cristillo, Anthony; Pantaleo, Giuseppe; Levy, Yves.
Afiliação
  • Zurawski G; Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, and Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, service d'immunologie clinique, Créteil, France.
  • Shen X; Baylor Institute for Immunology Research and INSERM U955, Dallas, Texas, USA.
  • Zurawski S; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
  • Tomaras GD; Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, and Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, service d'immunologie clinique, Créteil, France.
  • Montefiori DC; Baylor Institute for Immunology Research and INSERM U955, Dallas, Texas, USA.
  • Roederer M; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
  • Ferrari G; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
  • Lacabaratz C; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
  • Klucar P; Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA.
  • Wang Z; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
  • Foulds KE; Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, and Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, service d'immunologie clinique, Créteil, France.
  • Kao SF; Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, and Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, service d'immunologie clinique, Créteil, France.
  • Yu X; Baylor Institute for Immunology Research and INSERM U955, Dallas, Texas, USA.
  • Sato A; Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, and Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, service d'immunologie clinique, Créteil, France.
  • Yates NL; Baylor Institute for Immunology Research and INSERM U955, Dallas, Texas, USA.
  • LaBranche C; Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA.
  • Stanfield-Oakley S; Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA.
  • Kibler K; Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Jacobs B; Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Salazar A; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
  • Self S; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
  • Fulp W; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
  • Gottardo R; School of Life Sciences, Center for Infectious Diseases and Vaccinology, Arizona State University, Tempe, Arizona, USA.
  • Galmin L; School of Life Sciences, Center for Infectious Diseases and Vaccinology, Arizona State University, Tempe, Arizona, USA.
  • Weiss D; Oncovir, Washington, DC, USA.
  • Cristillo A; Vaccine and Infectious Disease and Public Health Sciences Divisions, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Pantaleo G; Vaccine and Infectious Disease and Public Health Sciences Divisions, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Levy Y; Vaccine and Infectious Disease and Public Health Sciences Divisions, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
J Virol ; 91(9)2017 05 01.
Article em En | MEDLINE | ID: mdl-28202751
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / Linfócitos T CD4-Positivos / HIV-1 / Vacinas contra a AIDS / Linfócitos T CD8-Positivos / Antígenos CD40 / Receptores Depuradores Classe E / Produtos do Gene env do Vírus da Imunodeficiência Humana Limite: Animals Idioma: En Revista: J Virol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / Linfócitos T CD4-Positivos / HIV-1 / Vacinas contra a AIDS / Linfócitos T CD8-Positivos / Antígenos CD40 / Receptores Depuradores Classe E / Produtos do Gene env do Vírus da Imunodeficiência Humana Limite: Animals Idioma: En Revista: J Virol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: França